Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.

MLA

Weiss, Jared, et al. “Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.” Clinical Lung Cancer, vol. 22, no. 5, Sept. 2021, pp. 449–60. EBSCOhost, https://doi.org/10.1016/j.cllc.2021.03.010.

APA

Weiss, J., Goldschmidt, J., Andric, Z., Dragnev, K. H., Gwaltney, C., Skaltsa, K., Pritchett, Y., Antal, J. M., Morris, S. R., & Daniel, D. (2021). Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clinical Lung Cancer, 22(5), 449–460. https://doi.org/10.1016/j.cllc.2021.03.010

Chicago

Weiss, Jared, Jerome Goldschmidt, Zoran Andric, Konstantin H Dragnev, Chad Gwaltney, Konstantina Skaltsa, Yili Pritchett, Joyce M Antal, Shannon R Morris, and Davey Daniel. 2021. “Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.” Clinical Lung Cancer 22 (5): 449–60. doi:10.1016/j.cllc.2021.03.010.